Charles Schwab
AVNR

Charles Schwab’s AVANIR PHARMACEUTICALS, INC CL A AVNR Stock Holding History

Charles Schwab’s Portfolio AVNR Stock Details AVNR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-518,515
Closed -$8.79M – 3125
2014
Q4 		$8.79M Buy
518,515
+62,932
+14% +$885K 0.01% 986
2014
Q3 		$5.43M Buy
455,583
+39,362
+9% +$269K 0.01% 1293
2014
Q2 		$2.35M Buy
416,221
+29,740
+8% +$137K ﹤0.01% 1896
2014
Q1 		$1.42M Buy
386,481
+32,560
+9% +$124K ﹤0.01% 2119
2013
Q4 		$1.19M Sell
353,921
-19,290
-5% -$79.7K ﹤0.01% 2187
2013
Q3 		$1.64M Buy
373,211
+37,692
+11% +$179K ﹤0.01% 1966
2013
Q2 		$1.51M Buy
+335,519
New +$1.15M ﹤0.01% 1926

Charles Schwab's AVNR Position: Q1 2015 in Review

Charles Schwab sold out of AVANIR PHARMACEUTICALS, INC CL A (AVNR) in Q1 2015, closing a stake of 518,515 shares — an estimated $8.79M sold.

Charles Schwab first reported a position in AVNR in Q2 2013 and held it in 7 quarters. The position peaked at $8.79M in Q4 2014. 0 funds tracked by Wall St. Rank hold AVNR as of Q1 2015.

  • Charles Schwab reported no remaining AVANIR PHARMACEUTICALS, INC CL A position as of Q1 2015 after selling out during the quarter.
  • Charles Schwab sold 518,515 AVANIR PHARMACEUTICALS, INC CL A shares in Q1 2015, an estimated $8.79M.
  • Charles Schwab first reported a position in AVANIR PHARMACEUTICALS, INC CL A in Q2 2013 and held it in 7 quarters.
  • Charles Schwab's AVANIR PHARMACEUTICALS, INC CL A position peaked at $8.79M in Q4 2014.
  • 0 funds tracked by Wall St. Rank held AVANIR PHARMACEUTICALS, INC CL A as of Q1 2015.

Based on Charles Schwab's 13F filing for Q1 2015, filed 14 May 2015.